

# Drug Coverage Decision for B.C. PharmaCare

## About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

## Details of Drug Reviewed

<b>Drug</b>	<b>Pegfilgrastim</b>
Brand Name	Fulphila™
Dosage Form(s)	6 mg/0.6 mL (10 mg/mL) Prefilled Syringe
Manufacturer	BGP Pharma ULC
<b>Submission Type</b>	<b>New Submission</b>
Use Reviewed	Fulphila was reviewed for the following indication: to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs.
Common Drug Review (CDR)	CDR reviewed Fulphila as a biosimilar submission.
Provincial Review	Biosimilars are not reviewed by the Drug Benefit Council (DBC) and the Ministry's drug coverage decision was based on an internal review.
<b>Drug Coverage Decision</b>	<b>Non-Benefit</b>
Date	February 11, 2020
Reason(s)	<ul style="list-style-type: none"> <li>Fulphila is a biosimilar of pegfilgrastim (Neulasta®). Based on the Health Canada review, Fulphila is similar to Neulasta with respect to efficacy, safety, pharmacokinetics and immunogenicity.</li> <li>Neulasta is not an eligible PharmaCare benefit due to an increased cost compared to filgrastim; it also provides no additional clinical benefit of significance. The review of Neulasta was completed in 2010.</li> <li>Lastly, Fulphila is more costly than the biosimilar filgrastim (Grastofil®).</li> </ul>
Other Information	None

### **The Drug Review Process in B.C.**

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council \(DBC\)](#) gives advice to the Ministry. The DBC looks at:

- whether the drug is safe and effective
- advice from a national group called the [Common Drug Review \(CDR\)](#)
- what the drug costs and whether it is a good value for the people of B.C.
- ethical considerations involved with covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes PharmaCare coverage decisions by taking into account:

- the existing PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- the drugs already covered by PharmaCare that are used to treat similar medical conditions
- the overall cost of covering the drug

Visit [The Drug Review Process in B.C. - Overview](#) and [Ministry of Health - PharmaCare](#) for more information.

**This document is intended for information only.**

It does not take the place of advice from a physician or other qualified health care provider.